NIDDK BPH and Male LUTS Workshop

This event has passed.

@ 11:00 am EDT - @ 4:00 pm EDT
More Information

All virtual, over 3 days

11-4:00 PM Eastern each day (10-3 PM Central | 8-1 PM Pacific)

Check event website often for up to date information

Workshop Objectives:

Are male LUTS and BPH syndromic? Or should male LUTS be re-examined within the framework of separating prostate pathology from bladder pathology? New insights emergent in the last few years regarding BPH and bladder dysfunction etiology and significant advances in our understanding of the biology of aging make this an opportune time to come to a new understanding of BPH etiology, prostate pathology, and male LUTS.


Workshop is now virtual. Register by March 24, 2022. Speakers at this NIDDK workshop – organized by NIDDK Program Officer Tracy Rankin, PhD, MPH – will address insights from basic science research, clinical/translational science, and epidemiology and include:

  • Will Ricke, PhD (PI, UW-Madison U54 Urology O’Brien Center)
  • James Brooks, MD (PI, Stanford University U54 Urology O’Brien Center)
  • Janet Keast, PhD (University of Melbourne)
  • Doug Strand, PhD (UTSW, Project Leader, UW-Madison U54 Urology O’Brien Center)
  • Tina Hernandez-Boussard, PhD (Stanford University)
  • Marvin Langston, PhD, MPH (Kaiser Permanente and K12 Scholar alumnus, UCSF-Kaiser Permanente KUroEpi Program)
  • Teresa Liu, PhD (UW-Madison U54 Urology O’Brien Center and K12 Scholar alumnus, UW-Madison KURe Program)
  • Chad Vezina, PhD (Project Leader, UW-Madison U54 Urology O’Brien Center)
  • Brian Helfand, MD (Northwestern University)

Other notable speakers include: Ramy Goueli, MD and Claus Roehrborn, MD (UTSW), Travis Jerde, PhD (Indiana University), Aria Olumi, MD (Beth Israel Deaconess Medical Center), and Peter Caravan, PhD (Massachusetts General Hospital)

BACKGROUND: Benign prostatic hyperplasia (BPH) affects 50% of men over age 50. Ninety percent of men over age 80 become affected. Often men with BPH present with lower urinary tract symptoms (LUTS) and first-line treatment of such symptoms include medical management with 5a-reductase inhibitors to reduce prostate size and alpha-blockers to relax the urinary sphincter. Surgical therapies to resect the prostate can also be effective. However, many men do not find symptom relief from these prostate-targeted treatments, and prostate size is often not correlated with severity of urinary symptoms.